DK2837680T3 - Mammaliacellekultur - Google Patents

Mammaliacellekultur Download PDF

Info

Publication number
DK2837680T3
DK2837680T3 DK14187232.5T DK14187232T DK2837680T3 DK 2837680 T3 DK2837680 T3 DK 2837680T3 DK 14187232 T DK14187232 T DK 14187232T DK 2837680 T3 DK2837680 T3 DK 2837680T3
Authority
DK
Denmark
Prior art keywords
cell culture
mammalia
mammalia cell
culture
cell
Prior art date
Application number
DK14187232.5T
Other languages
English (en)
Inventor
Brian D Follstad
Rebecca E Mccoy
Arvia E Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2837680(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2837680T3 publication Critical patent/DK2837680T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK14187232.5T 2011-07-01 2012-06-29 Mammaliacellekultur DK2837680T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01
EP12738674.6A EP2726600B1 (en) 2011-07-01 2012-06-29 Mammalian cell culture

Publications (1)

Publication Number Publication Date
DK2837680T3 true DK2837680T3 (da) 2020-04-27

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14187232.5T DK2837680T3 (da) 2011-07-01 2012-06-29 Mammaliacellekultur
DK12738674.6T DK2726600T3 (da) 2011-07-01 2012-06-29 Pattedyrcellekultur

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12738674.6T DK2726600T3 (da) 2011-07-01 2012-06-29 Pattedyrcellekultur

Country Status (23)

Country Link
US (7) US11292829B2 (da)
EP (2) EP2837680B1 (da)
JP (1) JP5897708B2 (da)
KR (7) KR20230114317A (da)
CN (2) CN103827292B (da)
AU (5) AU2012279230C1 (da)
BR (2) BR112013033730B1 (da)
CA (2) CA2838695C (da)
CL (2) CL2013003792A1 (da)
CY (2) CY1118863T1 (da)
DK (2) DK2837680T3 (da)
EA (1) EA039023B1 (da)
ES (2) ES2625045T3 (da)
HU (2) HUE033279T2 (da)
IL (6) IL297998B2 (da)
LT (2) LT2726600T (da)
MX (2) MX387489B (da)
PL (2) PL2726600T3 (da)
PT (2) PT2726600T (da)
SG (1) SG10201702537RA (da)
SI (2) SI2726600T1 (da)
WO (1) WO2013006479A2 (da)
ZA (1) ZA201309372B (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
AU2012326170B2 (en) 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
US20150353542A1 (en) * 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SG10201802023RA (en) * 2013-03-26 2018-05-30 Coherus Biosciences Inc Protein production method
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
SI3063287T1 (sl) * 2013-10-31 2025-06-30 Amgen, Inc. Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
CA2969225C (en) * 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
AU2017206012A1 (en) * 2016-01-06 2018-07-26 Outlook Therapeutics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
IL261411B2 (en) * 2016-03-02 2024-03-01 Lonza Ag Improved fermentation process
CN110462054B (zh) * 2017-03-31 2023-11-10 勃林格殷格翰国际公司 灌注培养基
WO2018178069A1 (en) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
CN110945593A (zh) * 2017-06-16 2020-03-31 通用电气健康护理生物科学股份公司 用于预测生物反应器中的过程的产出和对生物反应器中的过程建模的方法
KR102755437B1 (ko) 2017-08-09 2025-01-20 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
WO2019071076A1 (en) 2017-10-06 2019-04-11 Lonza Ltd. AUTOMATED CONTROL OF CELL CULTURE BY SPECTROSCOPY RAMAN
HUE058924T2 (hu) 2017-10-16 2022-09-28 Regeneron Pharma Perfúziós eljárások
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN119193493A (zh) * 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
IL279782B2 (en) * 2018-07-03 2026-05-01 Bristol Myers Squibb Co Methods for producing recombinant proteins
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
JP2022516516A (ja) * 2018-12-31 2022-02-28 レプリゲン・コーポレーション 疎水性中空繊維による哺乳類細胞培養物の灌流および浄化用フィルター
WO2021058713A1 (en) * 2019-09-27 2021-04-01 Boehringer Ingelheim International Gmbh Concentrated perfusion medium
EP4196597A2 (en) * 2020-08-14 2023-06-21 Bristol-Myers Squibb Company Manufacturing process for protein
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
AR130495A1 (es) 2022-09-16 2024-12-11 Amgen Inc Un método para recoger productos a partir de cultivos en perfusión
WO2024220354A1 (en) * 2023-04-15 2024-10-24 Puerto Rico Science Technology & Research Trust Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof
WO2025029614A1 (en) 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
PL1720972T3 (pl) * 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
EP2246075A1 (en) 2004-07-07 2010-11-03 Coloplast A/S Preparation of hydrophilic coatings utilizing a 1,3-dioxolane compound
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
CA2609060C (en) * 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
FI2343362T4 (fi) 2006-07-14 2024-07-04 Patheon Holdings I B V Parannettu menetelmä solujen viljelyä varten
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
MX2009004974A (es) 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
AU2009290563A1 (en) 2008-09-15 2010-03-18 Genentech, Inc. Compositions and methods for regulating cell osmolarity
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
NZ597727A (en) 2009-07-31 2013-08-30 Baxter Int Cell culture medium for adamts protein expression
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2012059857A2 (en) * 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
SI2726600T1 (sl) * 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
SI3063287T1 (sl) 2013-10-31 2025-06-30 Amgen, Inc. Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
IL259404B2 (en) * 2015-11-17 2025-08-01 Pfizer Media and fermentation methods for producing polysaccharides in bacterial cell culture

Also Published As

Publication number Publication date
EA039023B1 (ru) 2021-11-23
MX351974B (es) 2017-11-06
US20230117598A1 (en) 2023-04-20
CA2952347A1 (en) 2013-01-10
CA2838695C (en) 2017-02-14
KR101662412B1 (ko) 2016-10-04
KR101857380B1 (ko) 2018-05-11
AU2018203972C1 (en) 2025-06-26
KR102358951B1 (ko) 2022-02-08
CN103827292B (zh) 2018-01-26
KR20180050433A (ko) 2018-05-14
HUE033279T2 (en) 2017-11-28
IL278430B (en) 2022-01-01
PT2726600T (pt) 2017-04-24
IL297998B1 (en) 2024-03-01
KR20140031375A (ko) 2014-03-12
KR102558247B1 (ko) 2023-07-24
KR20240005106A (ko) 2024-01-11
EA201391826A1 (ru) 2014-04-30
JP2014520534A (ja) 2014-08-25
KR20230114317A (ko) 2023-08-01
EP2726600B1 (en) 2017-02-15
PT2837680T (pt) 2020-04-17
IL310968B2 (en) 2025-03-01
WO2013006479A3 (en) 2013-03-28
SI2726600T1 (sl) 2017-07-31
IL310968A (en) 2024-04-01
CY1118863T1 (el) 2018-01-10
BR112013033730A2 (pt) 2017-01-31
AU2012279230B2 (en) 2016-08-18
US20220185869A1 (en) 2022-06-16
ZA201309372B (en) 2014-08-27
HUE049119T2 (hu) 2020-09-28
AU2016244255A1 (en) 2016-10-27
US20140255993A1 (en) 2014-09-11
US11634476B2 (en) 2023-04-25
AU2012279230C1 (en) 2025-06-19
LT2837680T (lt) 2020-07-10
IL229803B (en) 2020-11-30
EP2726600A2 (en) 2014-05-07
DK2726600T3 (da) 2017-05-15
HK1206057A1 (en) 2015-12-31
CN103827292A (zh) 2014-05-28
AU2023201127B2 (en) 2025-10-16
ES2625045T3 (es) 2017-07-18
US20230129523A1 (en) 2023-04-27
BR112013033730B1 (pt) 2022-01-25
IL310968B1 (en) 2024-11-01
WO2013006479A2 (en) 2013-01-10
KR102761360B1 (ko) 2025-02-05
AU2012279230A1 (en) 2014-01-09
IL315908A (en) 2024-11-01
US11292829B2 (en) 2022-04-05
CY1123146T1 (el) 2021-12-31
AU2018203972B2 (en) 2020-09-17
SI2837680T1 (sl) 2020-07-31
AU2020281075A1 (en) 2021-01-07
US11673941B2 (en) 2023-06-13
IL297998A (en) 2023-01-01
PL2837680T3 (pl) 2020-08-10
CL2013003792A1 (es) 2014-07-25
KR20160075814A (ko) 2016-06-29
KR20250021605A (ko) 2025-02-13
IL288509B2 (en) 2023-04-01
US20200407427A1 (en) 2020-12-31
US20210061888A1 (en) 2021-03-04
KR102108663B1 (ko) 2020-05-07
EP2837680B1 (en) 2020-02-26
LT2726600T (lt) 2017-05-25
CL2016001190A1 (es) 2017-06-09
HK1197081A1 (en) 2015-01-02
AU2023201127A1 (en) 2023-03-30
US20230227535A1 (en) 2023-07-20
AU2018203972A1 (en) 2018-06-21
AU2020281075C1 (en) 2025-06-26
KR20220021008A (ko) 2022-02-21
US11827692B2 (en) 2023-11-28
SG10201702537RA (en) 2017-04-27
JP5897708B2 (ja) 2016-03-30
EP2837680A1 (en) 2015-02-18
CN107988166A (zh) 2018-05-04
BR122021007265B1 (pt) 2022-02-22
IL297998B2 (en) 2024-07-01
CA2838695A1 (en) 2013-01-10
AU2020281075B2 (en) 2022-12-22
US11685772B2 (en) 2023-06-27
IL288509A (en) 2022-01-01
ES2788132T3 (es) 2020-10-20
MX2013014937A (es) 2014-04-16
KR20200051046A (ko) 2020-05-12
IL288509B (en) 2022-12-01
CN107988166B (zh) 2022-03-15
MX387489B (es) 2025-03-18
PL2726600T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
EP2681306A4 (en) CELL CULTURE SYSTEM
IL229803B (en) Mammalian cell culture
EP2788470A4 (en) CLOSED BIOREACTORS
DK2900806T3 (da) Tredimensionel celledyrkning
DK2775557T3 (da) Brændselscelle
EP2673344A4 (en) STABLE BIO OIL
EP2743171A4 (en) LIQUID NATURAL GAS VEHICLES
DK3812453T3 (da) Metabolisk optimeret cellkultur
EP3719852C0 (en) SOLAR CELL
EP2709128A4 (en) ELECTROCHEMICAL CELL
EP2751846A4 (en) SOLAR CELL
BR112014000879A2 (pt) deflegmador
EP2717322A4 (en) SOLAR CELL
EP2729605A4 (en) RNA YY1 INTERACTIONS
CO6960543A2 (es) 2-tiopirimidinonas
EP2731657A4 (en) HUMIDIFIERS
EP2794841A4 (en) BIOREACTOR
EP2744740A4 (en) BOOM STRUCTURE
EP2691987A4 (en) PHOTOVOLTAIC STRUCTURE
EP2757623A4 (en) FUEL CELL
EP2795304A4 (en) ELECTROCHEMICAL SENSORS
DK2681530T3 (da) Gennemstrømmelig målecelle
DE112011105455T8 (de) Brennstoffzelle
EP2768053A4 (en) FUEL CELL
EP2842166A4 (en) CELL ARRANGEMENT